PraXsyn Sales Approximately $11M for April; Up From $8.8M in March

PraXsyn Corporation

(OTCQB:PAWS) announces that after reporting March sales of $8.8M, April sales have increased to approximately $11M. "We are excited about the growth in sales, and we are looking forward to continued growth," said Dan Wiesel CEO of PraXsyn. Additionally, PraXsyn has asked DBB McKennon to become the company's new auditor. With the business in rapid growth, we felt that a local auditor would be more efficient working with the PraXsyn management team. The 8K has been accepted by the SEC this morning.

Our goal at the new PraXsyn to is provide medical practitioners with products and services to help them help their patients. Our Mesa Pharmacy division currently provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and clinics. Mesa has developed a series of topical creams, in different strengths, that provide the pain relief doctors seek.

About PraXsyn, Inc.

PraXsyn, Inc. is dedicated to providing medical practitioners with medications and services for their patients. We currently formulate transdermal creams in our compounding pharmacy, Mesa Pharmacy. These are geared to patients suffering from long-term pain associated with work place related injuries.

For additional information go to www.praxsyn.com


Forward-Looking Statements

Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.

CONTACT: Company Contact: [e-mail]